Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
SILO PHARMA INC (SILO) Stock Price & Overview
NASDAQ:SILO • US82711P2011
Current stock price
0.455 USD
+0.01 (+2.92%)
At close:
0.4557 USD
+0 (+0.15%)
After Hours:
The current stock price of SILO is 0.455 USD. Today SILO is up by 2.92%. In the past month the price increased by 31.66%. In the past year, price decreased by -39.33%.
SILO Key Statistics
52-Week Range0.221 - 1.1299
Current SILO stock price positioned within its 52-week range.
1-Month Range0.3435 - 0.695
Current SILO stock price positioned within its 1-month range.
- Market Cap
- 6.447M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
SILO Stock Performance
Today
+2.92%
1 Week
-9.00%
1 Month
+31.66%
3 Months
+31.85%
Longer-term
6 Months -15.99%
1 Year -39.33%
2 Years -78.13%
3 Years -79.21%
5 Years N/A
10 Years N/A
SILO Stock Chart
SILO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SILO. When comparing the yearly performance of all stocks, SILO is a bad performer in the overall market: 74.76% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
SILO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILO. While SILO has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SILO Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
SILO Forecast & Estimates
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-2.86%
Revenue Next Year0%
SILO Financial Highlights
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 48.85% compared to the year before.
Income Statements
Revenue(TTM)72.00K
Net Income(TTM)-4.23M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.59% | ||
| ROE | -67.05% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%82.9%
Sales Q2Q%0%
EPS 1Y (TTM)48.85%
Revenue 1Y (TTM)0%
SILO Ownership
Ownership
Inst Owners8.57%
Shares14.17M
Float16.04M
Ins Owners1.57%
Short Float %3.26%
Short Ratio0.09
SILO Industry Overview
SILO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
SILO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SILO
Company Profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Company Info
IPO: 2012-01-05
SILO PHARMA INC
677 N Washington Blvd
Sarasota FLORIDA US
Employees: 3
Phone: 17184009031
SILO PHARMA INC / SILO FAQ
What does SILO do?
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
What is the stock price of SILO PHARMA INC today?
The current stock price of SILO is 0.455 USD. The price increased by 2.92% in the last trading session.
Does SILO stock pay dividends?
SILO does not pay a dividend.
What is the ChartMill rating of SILO PHARMA INC stock?
SILO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for SILO PHARMA INC?
SILO PHARMA INC (SILO) currently has 3 employees.
What is SILO PHARMA INC worth?
SILO PHARMA INC (SILO) has a market capitalization of 6.45M USD. This makes SILO a Nano Cap stock.
What is the Short Interest ratio of SILO PHARMA INC (SILO) stock?
The outstanding short interest for SILO PHARMA INC (SILO) is 3.26% of its float.